AHB-137 monotherapy Elicits High Functional Cure Rates and Sustained DNA Suppression in Treatment-Naïve Chronic Hepatitis B Participants: Results from an Ongoing Phase II Study

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


AHB-137 monotherapy Elicits High Functional Cure Rates and Sustained DNA Suppression in Treatment-Naïve Chronic Hepatitis B Participants: Results from an Ongoing Phase II Study T

	EASL 2026 May 26-30 Barcelona Yunqing Qiu1*,